165 results about "Overall survival" patented technology

An apparatus, method and computer program product is presented to address early visual-sensory motor perception of a subject, where the method comprising the steps of: (1) controlling photic energetic parameters and/or photic perceptual attributes to trigger pre-attentive cuing or increase reactivity in magnocellular activity towards transient visual stimuli of the subject; and (2) generating a optical field comprising optical events based on said photic energetic parameters and said photic perceptual attributes, wherein said optical field transforms into a simple optical flow in the perceptual visual field of said subject. The photic energetic parameters may comprise light array energetic features, including one or more of wavelength, amplitude, intensity, phase, polarization, coherence, hue, brightness, and saturation.

The application describes methods for predicting overall survival in subjects with breast cancer. The application also describes for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including gemcitabine. The application further describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including gemcitabine and administering the therapy in subjects when it is found that gemcitabine is likely to be effective.

The present invention relates to a method for prognosing cancer in a subject with triple negative (TN) breast cancer, whose tumors lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and normal (not amplified) levels of the human epidermal growth factor receptor 2 (HER2). Methods and biomarkers are disclosed that are useful for predicting the overall survival (OS) potential of cancer in a subject with triple negative breast cancer or for predicting metastatic disease in a subject with triple negative breast cancer. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANK3, CD24, EIF1, KLF6, KRAS, KRT1, MAP2K4, SDC4, SLC2A3, STK3, TFAP2C, and WRN. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of OS of TN breast cancer. Likewise, in another example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANG, DICER1, EIF1, and MSH6. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of metastasis of TN breast cancer.

We analyzed bone marrow from 67 patients from a phase 2 study of farnesyltransferase inhibition with tipifarnib (R115777, ZARNESTRA®), in older adults with previously untreated, poor-risk acute myeloid leukemia (AML) for N-Ras mutations, global gene expression, and/or quantitative PCR (qPCR) of specific genes. Microarray profiling identified a two-gene expression ratio (RASGRP1:APTX) which provided the greatest accuracy for predicting response to tipifarnib. We demonstrated that this classifier could predict response to tipifarnib in an independent set of 54 samples from relapsed or refractory AML, with a NPV and PPV of 92% and 28%, respectively (odds ratio of 4.4). Therefore, in both newly diagnosed and relapsed or refractory AML, this classifier improves the overall response rate by approximately 50% while maintaining a high NPV, and significantly improves patient overall survival. The two-gene classifier was also validated by qPCR in thirty AML samples from the same clinical study demonstrating a negative predictive value (NPV) and positive predictive value (PPV) of 81% and 50%, respectively (odds ratio of 4.3). These data indicate that a simple two-gene expression assay may have utility in diagnosing a population of AML patients who are more likely to respond to tipifarnib.

The invention provides methods for reducing the incidence and/or severity and/or delaying the onset of heart dysfunction/failure and improving overall survival through the use of remote ischemic per-conditioning and post-conditioning.

The invention relates to an immune gene prognosis model for predicting hepatocellular carcinoma tumor immune infiltration and postoperative survival time, and belongs to the technical field of biological medicines. The model can be used for evaluating the infiltration degree of immune cells in a tumor in clinical practice by detecting the expression levels of 22 specific immune related genes of ahepatocellular carcinoma patient, so that the model can be used for predicting hepatocellular carcinoma tumor immune infiltration in clinical practice and improve the prediction capability of the liver cancer immunotherapy response. The model can be used for judging the postoperative overall survival risk of a patient and guiding the formulation of a postoperative treatment strategy, and the corresponding microarray chip kit can realize the standardization and convenience of detection. Meanwhile, the immune gene prognosis model provided by the invention can increase the prediction accuracy andthe clinical net income of a hepatocellular carcinoma TNM staging system on the total survival time of three years and five years after operation. As a molecular marker for objectively and accuratelyevaluating the tumor immune state and poor prognosis risk of hepatocellular carcinoma, the model can realize accurate implementation of hepatocellular carcinoma immunotherapy and accurate prognosis prediction.

A method of determining a state of ventricular fibrillation from a waveform, includes: performing calculations on the Fourier transform of the waveform voltage values by using the quotient of the power in a high frequency band and of the power in a low frequency band; and determining the state of ventricular fibrillation by relating this ratio to the state of ventricular fibrillation. A defibrillation system for use in treatment of ventricular fibrillation includes at least one sensor to measure heart rhythm and at least one applicator to apply a defibrillation shock to a patient. The system further includes at least one processor which is adapted to calculate the ratio and also to obtain user input regarding survival of subgroups and average response times in the user's domain which allows calculation of an estimated maximum overall survival and selection of an optimum threshold for the ratio measure based on this maximum. The system further includes a user interface system in operative connection with the processor to provide information related to the ratio to a user.

A method for the prognosis of overall survival or prediction of therapeutic outcome for a patient suffering from epithelial ovarian cancer (EOC), comprising: a. providing a sample from the patient, b. determining the expression level of microRNA family lethal-7b (let-7b) in the sample; c. using the expression level of the let-7b to obtain the prognosis of overall survival or prediction of therapeutic outcome for the patient.

The invention discloses a specific scheme of wireless sensor network target tracking for energy conservation, which is used for accurately tracking the state of a target under the conditions of energy consumption constraint, topology switching and the like. The working mode of each node in a network is dynamically planned according to the energy consumption of each node and changes of the external condition, so that a net topology is dynamically switched to reduce the network energy consumption. Each node in a tracking network tracks the state information of a target in real time by acquiring target data and performing information exchange with neighbor nodes. By adopting the specific scheme of wireless sensor network target tracking, the influence of dynamic changes of a network topological structure on the overall performance of the tracking network can be quantitatively analyzed, the highest switching frequency for guaranteeing normal work of the tracking network is determined, and on the premise of ensuring the network overall survival time, the robustness and tracking accuracy of the tracking network are improved, and a specific deployment scheme of a network system is provided.

MicroRNA profiles transition from normal breast to ductal carcinoma in situ and transition to invasive ductal carcinoma (IDC) and methods of use thereof are described. Methods of diagnosis and prognosis using microRNA signatures to differentiate invasive from in situ carcinoma are described. Also described is the use of microRNA expression for predicting overall survival and time to metastasis.

The present invention relates to markers and diagnostic reagents for the diagnosis or prognosis of lung cancer. The present invention discloses for the first time that DDX56 is significantly increasedin patients with early disease progression (= 12 months) after treatment of two major subtypes of small cell lung cancer (lung squamous cell carcinoma, lung adenocarcinoma), and that the increased expression of DDX56 significantly affects the overall survival of the patients. Therefore, DDX56 can be used as a diagnostic marker for early recurrence of lung squamous cell carcinoma or lung adenocarcinoma.

The invention provides a gene combination and application thereof in preparation of a reagent for predicting prognosis of a patient treated with an immune checkpoint inhibitor. Based on the combination of 55 genes, the invention develops a tumor mutation score TMS32055 method through the gene combination, and TMS is defined as the number of genes containing non-synonymous mutations in a specific gene combination. TMS 55 is divided into 3 groups: TMS 55 is equal to 0, TMS 55 is greater than or equal to 1 and is less than or equal to 5, and TMS 55 is greater than 5. Compared with a group that TMS 55 is equal to 0, the patients of groups that TMS 55 is greater than or equal to 1 and is less than or equal to 5 and TMS 55 is greater than 5 have better prognosis and longer overall survival time.The TMS55 based on the 55-gene combination has higher prediction efficiency than TMB in predicting the overall survival after immunotherapy, and has uniform cutoff value. Therefore, the TMS55 can beused for predicting the prognosis of patients receiving immune checkpoint inhibition treatment, and is easier to popularize and apply in clinical practice.

Cytokeratin (CK)+/CD45−/DAPI+ cells in the blood of cancer patients have been considered by most as circulating tumor cells (CTCs). Different methods of isolating CTCs results in a wide range of numbers and subgroups of CTCs from same patient. As a result, the clinical significance of the number of CTCs becomes cloudy. Provided herein is methodology to categorize CTCs into morphologically distinct subpopulations, and to use one of the subpopulations in methods for predicting overall survival of a patient having cancer.

Measurement of a single gene expressed by tumor cells (LMO2) and a single gene expressed by the immune microenvironment (TNFRSF9), which determination may be referred to herein as a two gene score (TGS), powerfully predicts overall survival in patients with NHL, particularly overall survival in the context of anthracycline-based chemotherapy or co-treatment with anthracycline-based chemotherapy and anti-CD20 immunotherapy. It is shown herein that increased levels of LMO2 and TNFRSF9 correlate with a positive patient response and improved prognosis.

The invention provides a joint detection kit for multiple stem cell markers on surfaces of CTCs (circulating tumor cells) and an application of the kit. The joint detection kit for multiple stem cellmarkers on surfaces of CTCs comprises 1) a peripheral blood CTC enrichment reagent; 2) an RNA extraction reagent; 3) an RNA reverse transcription reagent; 4) a fluorescence labeled Taqman probe and aspecific primer; 5) a qPCR reaction system reagent and a hepatocellular carcinoma prediction formula. The kit can be used for biopsy of minimally invasive fluids of tumor patients, early diagnosis andearly warning of tumor metastasis and relapse are realized, the anti-tumor therapy effect and the tumor progression condition are monitored, molecular subtyping based on CTCs and screening of specific sensitive drugs for the CTCs are realized, so that knowledge about tumor metastasis, relapse and drug resistance related mechanisms is improved, individualized medical treatment of tumor patients isguided, the overall survival of the tumor patients is significantly improved, and the kit has great clinical significance.

Despite initial sensitivity BAD-protein phosphorylation were evaluated in patient samples and cell lines as determinants of chemo-sensitivity and/or clinical outcome, and as therapeutic targets. Induced in-vitro OVCA cisplatin-resistance was associated with BAD-pathway expression. Expression of the pathway was also associated with resistance of 7 different cancers cell-types to 8 chemotherapeutic agents. Phosphorylation of the BAD-protein was associated with platinum-resistance in OVCA cells and primary OVCA specimens, and also overall patient survival. Targeted modulation of BAD-phosphorylation levels influenced cisplatin-sensitivity. A 47-gene BAD-pathway signature was associated in-vitro phospho-BAD levels and with survival of 838 patients with ovarian, breast, colon, and brain cancer. The survival advantage associated with both BAD-phosphorylation and also the BAD-pathway signature was independent of surgical cytoreductive status. The BAD apoptosis pathway influences human cancer chemo-sensitivity and overall survival. The pathway is useful as a biomarker of therapeutic response, patient survival, and therapeutic target.